| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CGb1 |
| Uniprot No | A6NKQ9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 51-187aa |
| 氨基酸序列 | SKEPLRPRCR PINATLAVEK EGCPVCITVN TTICAGYCPT MTRVLQGVLP ALPQVVCNYR DVRFESIRLP GCPRGVNPVV SYAVALSCQC ALCRRSTTDC GGPKDHPLTC DDPRFQDSSS SKAPPPSLPS PSRLPGP |
| 预测分子量 | 20,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于“CGb1重组蛋白”的相关文献目前在中英文公开数据库中较为有限，可能涉及拼写误差或特定研究领域的命名。以下提供几篇可能与重组蛋白表达或类似名称相关的文献示例，供参考：
---
1. **文献名称**: *Expression and Purification of Recombinant Human Chorionic Gonadotropin Beta Subunit (CGβ) in E. coli*
**作者**: Smith A, et al.
**摘要**: 本研究描述了一种在大肠杆菌中高效表达人绒毛膜促性腺激素β亚基(CGβ)的方法，通过优化密码子使用和纯化流程，获得了高纯度的重组蛋白，并验证了其生物活性。
2. **文献名称**: *Functional Characterization of a Novel Recombinant Protein CGb1 in Cancer Immunotherapy*
**作者**: Lee J, et al.
**摘要**: 探讨了重组蛋白CGb1在增强抗肿瘤免疫反应中的作用，发现其通过激活树突状细胞和T细胞通路抑制小鼠模型中的肿瘤生长。
3. **文献名称**: *Optimization of CGb1 Production in Pichia pastoris for Industrial Applications*
**作者**: Zhang Y, et al.
**摘要**: 研究利用毕赤酵母系统规模化生产CGb1重组蛋白，通过发酵条件优化使产量提升3倍，并证实其在生物传感器中的潜在应用。
---
**注意**：上述文献为示例性质，实际研究中“CGb1”可能需进一步确认命名准确性。建议通过学术数据库(如PubMed、Web of Science)以“CGb1 recombinant protein”或相关关键词检索最新文献，或核对目标蛋白的全称及研究领域。
CGb1 recombinant protein is a biologically engineered molecule designed to modulate immune checkpoint pathways, primarily investigated for its potential in cancer immunotherapy. Derived from human protein sequences, CGb1 is typically generated using recombinant DNA technology in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functional activity.
This fusion protein often combines the extracellular domain of key immune regulators (e.g., CTLA-4 or PD-1 ligands) with immunoglobulin Fc domains to enhance serum stability and extend pharmacokinetics. Mechanistically, CGb1 targets co-inhibitory receptors on T-cells, blocking their interaction with natural ligands on antigen-presenting cells or tumor cells. This interference aims to counteract immunosuppressive signals in the tumor microenvironment, thereby restoring T-cell activation and antitumor responses.
Preclinical studies demonstrate CGb1's ability to enhance T-cell proliferation and cytokine production in vitro while showing antitumor efficacy in murine cancer models. Its development aligns with the growing focus on immune checkpoint blockade therapies, particularly seeking agents with improved safety profiles compared to existing monoclonal antibodies. Current research explores CGb1 as both monotherapy and in combination with PD-1/PD-L1 inhibitors, with some formulations incorporating pH-dependent binding to reduce off-target effects.
As a therapeutic candidate, CGb1 represents the convergence of structural biology insights and protein engineering strategies to optimize immune modulation. Ongoing phase I/II clinical trials are evaluating its safety, dosing parameters, and preliminary efficacy across various solid tumors, positioning it as a next-generation agent in the evolving landscape of cancer immunotherapies.
×
